Despite advances in systemic chemotherapy, patients with gastric cancer (GC) and peritoneal metastases (PMs) continue to have poor prognoses. Intraperitoneal (IP) administration of Paclitaxel (PTX) combined with systemic chemotherapy shows promise in treating PMs from GC. However, methods of drug administration need to be optimized to maximize efficacy. In this study, we utilized a mouse model with PMs derived from a human GC cell line, administering PTX either IP or intravenously (IV), and Carboplatin (CBDCA) IV 0, 1, and 4 days after PTX administration. The PMs were resected 30 min later, and concentrations of PTX and CBDCA in resected tumors were measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Results indicated that PTX concentrations were higher with IP administration than with IV administration, with significant differences observed on days 0 and 1. CBDCA concentrations 4 days post-IP PTX administration were higher than with simultaneous IV PTX administration. These findings suggest that IP PTX administration enhances CBDCA concentration in peritoneal tumors. Therefore, sequential IV administration of anti-cancer drugs appears more effective than simultaneous administration with IP PTX, a strategy that may improve prognoses for patients with PMs.
尽管全身化疗已取得进展，胃癌伴腹膜转移患者的预后仍然较差。紫杉醇腹腔内给药联合全身化疗在治疗胃癌腹膜转移方面显示出潜力，但给药方式仍需优化以提升疗效。本研究采用人源胃癌细胞系构建的小鼠腹膜转移模型，分别通过腹腔或静脉途径给予紫杉醇，并于给药后第0、1、4天静脉注射卡铂。30分钟后切除腹膜转移灶，采用液相色谱-串联质谱法检测肿瘤组织中紫杉醇与卡铂的浓度。结果显示：腹腔给药组的紫杉醇浓度显著高于静脉给药组，其中第0天和第1天的差异具有统计学意义；紫杉醇腹腔给药4天后，肿瘤组织中的卡铂浓度高于紫杉醇静脉同步给药组。这些发现表明，紫杉醇腹腔给药能增强卡铂在腹膜肿瘤中的蓄积。因此，与紫杉醇腹腔给药同步化疗相比，序贯静脉给予抗癌药物可能更为有效，该策略有望改善腹膜转移患者的预后。
Optimizing Timing of Intraperitoneal Chemotherapy to Enhance Intravenous Carboplatin Concentration
肿瘤(癌症)患者之家